![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JE Fox-Threlkeld, EE Daniel, F Christinck, VJ Hruby, S Cipris and Z Woskowska
School of Nursing, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
Perfusion with ([N-Me-Phe3,D-Pro4]morphiceptin (PL017)), [D- Pen2,5]enkephalin (DPDPE) and MEt5 and Leu5 enkephalin induced circular muscle contractions and decreased immunoreactive vasoactive intestinal polypeptide (VIP) venous output in canine ileal segments. Motility and VIP responses to PL017 were abolished by the mu antagonist CTAP (D-Phe- Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) and unchanged by the delta antagonist ICI 174,864 ([N,N-dially-Tyr1,Aib2,3]Leu-enkephalin) which abolished DPDPE motility and VIP responses. The VIP response to DPDPE was unchanged by CTAP, which reduced motility responses, suggesting a DPDPE interaction with endogenous mu opioids, at a mu/delta(complexed) receptor. ICI 174,864 abolished Met5 and Leu5 enkephalin motility responses and Leu5 enkephalin VIP responses while CTAP was ineffective on Leu5 enkephalin motility responses or on both enkephalin VIP responses. CTAP increased Met5 enkephalin motility responses suggesting mu actions to inhibit excitatory nerves. ICI 174,864 reduced Met5 enkephalin VIP output decrements requiring CTAP addition for abolition, suggesting actions at mu/delta(complexed) receptors. Inhibition of nitric oxide synthase with N-omega-L-arginine methyl ester (L-NAME) abolished delta opioid and reduced by 30% mu opioid motility responses, leaving the VIP response intact. Hexamethonium and atropine abolished tonic VIP output, leaving intact motility responses to PL017 and DPDPE. Subsequently L-NAME eliminated delta opioid and reduced by 1/3 mu opioid motility responses. All opioids reduced the NO-mediated IJPs in myenteric plexus-free ileal circular muscle. Thus mu or delta opioids inhibit both NO and VIP release but removal of NO, not VIP, disinhibits circular muscle motility.
This article has been cited by other articles:
|
|
 |
|
  H. C. Lin, C. Neevel, and J. H. Chen Slowing intestinal transit by PYY depends on serotonergic and opioid pathways Am J Physiol Gastrointest Liver Physiol, April 1, 2004; 286(4): G558 - G563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Daniel, M. Anvari, J. E. T. Fox-Threlkeld, and T. J. McDonald Local, exendin-(939)-insensitive, site of action of GLP-1 in canine ileum Am J Physiol Gastrointest Liver Physiol, September 1, 2002; 283(3): G595 - G602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-T. Zhao, L. Wang, and H. C. Lin Slowing of intestinal transit by fat depends on naloxone-blockable efferent, opioid pathway Am J Physiol Gastrointest Liver Physiol, June 1, 2000; 278(6): G866 - G870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Porcher, Y. Julé, and M. Henry A Qualitative and Quantitative Study on the Enkephalinergic Innervation of the Pig Gastrointestinal Tract J. Histochem. Cytochem., March 1, 2000; 48(3): 333 - 344. [Abstract] [Full Text]
|
|
|
|
 |
|
 J.-A. E. T. Fox-Threlkeld, T. J. McDonald, Z. Woskowska, K. Iesaki, and E. E. Daniel Pituitary Adenylate Cyclase-Activating Peptide as a Neurotransmitter in the Canine Ileal Circular Muscle J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 66 - 75. [Abstract] [Full Text]
|
|
|
|
 |
|
 A Russo, R Fraser, K Adachi, M Horowitz, and G Boeckxstaens Evidence that nitric oxide mechanisms regulate small intestinal motility in humans Gut, January 1, 1999; 44(1): 72 - 76. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
